Key Highlights

Risk & Performance

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

Phase 2

4(80.0%)

Phase 4

1(20.0%)

5Total

Phase 2(4)

Phase 4(1)

Loading network data...

Showing 5 of 5 trials

Liposomal Doxorubicin and Gemcitabine in Treating Women With Metastatic Breast Cancer

Role: lead

Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma

Role: lead

Capecitabine in Treating Women With Advanced or Metastatic Breast Cancer

Role: lead

Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Role: lead

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Role: collaborator

All 5 trials loaded